Biodexa Pharmaceuticals

1.44
-0.10 (-6.49%)
At close: Apr 03, 2025, 3:59 PM
1.46
1.29%
After-hours: Apr 03, 2025, 07:58 PM EDT

Biodexa Pharmaceuticals Statistics

Share Statistics

Biodexa Pharmaceuticals has 1.45K shares outstanding. The number of shares has increased by 145.69% in one year.

Shares Outstanding 1.45K
Shares Change (YoY) 145.69%
Shares Change (QoQ) 0%
Owned by Institutions (%) n/a
Shares Floating 4.9M
Failed to Deliver (FTD) Shares 1.11K
FTD / Avg. Volume 0.07%

Short Selling Information

The latest short interest is 6.53K, so 1.12% of the outstanding shares have been sold short.

Short Interest 6.53K
Short % of Shares Out 1.12%
Short % of Float 0%
Short Ratio (days to cover) 0.38

Valuation Ratios

The PE ratio is 0 and the forward PE ratio is -85.8. Biodexa Pharmaceuticals's PEG ratio is 0.

PE Ratio 0
Forward PE -85.8
PS Ratio 0.01
Forward PS 0.7
PB Ratio 0
P/FCF Ratio 0
PEG Ratio 0
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Biodexa Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.1.

Current Ratio 1.26
Quick Ratio 1.26
Debt / Equity 0.1
Debt / EBITDA -0.06
Debt / FCF -0.07
Interest Coverage -195.46

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $18.14K
Profits Per Employee $-337.1K
Employee Count 21
Asset Turnover 0.04
Inventory Turnover n/a

Taxes

Income Tax -406K
Effective Tax Rate 5.42%

Stock Price Statistics

The stock price has increased by -94.62% in the last 52 weeks. The beta is 1.5, so Biodexa Pharmaceuticals's price volatility has been higher than the market average.

Beta 1.5
52-Week Price Change -94.62%
50-Day Moving Average 3.22
200-Day Moving Average 8.81
Relative Strength Index (RSI) 35.54
Average Volume (20 Days) 1.57M

Income Statement

In the last 12 months, Biodexa Pharmaceuticals had revenue of 381K and earned -7.08M in profits. Earnings per share was -224.13.

Revenue 381K
Gross Profit -3.69M
Operating Income -8.01M
Net Income -7.08M
EBITDA -7.16M
EBIT -7.44M
Earnings Per Share (EPS) -224.13
Full Income Statement

Balance Sheet

The company has 5.97M in cash and 464K in debt, giving a net cash position of 5.51M.

Cash & Cash Equivalents 5.97M
Total Debt 464K
Net Cash 5.51M
Retained Earnings -144.77M
Total Assets 13.97M
Working Capital 4.04M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -6.83M and capital expenditures -263K, giving a free cash flow of -7.09M.

Operating Cash Flow -6.83M
Capital Expenditures -263K
Free Cash Flow -7.09M
FCF Per Share -224.44
Full Cash Flow Statement

Margins

Gross margin is -967.45%, with operating and profit margins of -2103.41% and -1858.01%.

Gross Margin -967.45%
Operating Margin -2103.41%
Pretax Margin -1964.57%
Profit Margin -1858.01%
EBITDA Margin -1879.53%
EBIT Margin -2103.41%
FCF Margin -1860.63%

Dividends & Yields

BDRX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

Currently there are no analyst rating for BDRX.

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Stock Forecasts

Stock Splits

The last stock split was on Oct 4, 2024. It was a backward split with a ratio of 1:25.

Last Split Date Oct 4, 2024
Split Type backward
Split Ratio 1:25

Scores

Altman Z-Score -17.88
Piotroski F-Score 1